Last updated: May 23, 2026
Etodolac is supplied through a multi-tier network spanning API makers, contract manufacturers (finished dose), and specialty logistics for tablet and capsule distribution. However, specific supplier identities, plant-level roles (API vs. finished dose), and FDA market authorization linkage cannot be produced from the information provided.
If you want an actionable supplier map (API manufacturers, finished dose manufacturers, NDA/ANDA/labeler, key intermediates, and relevant FDA-registered facilities), no source details or identifiers (e.g., labeled products, NDCs, ANDA numbers, labeler names, or Orange Book entries) were supplied to anchor the list.
Key constraint: Without the labeled drug products (brand/generic, strength, dosage form), NDCs, or ANDA/NDA numbers, a complete and accurate “suppliers for etodolac” registry cannot be compiled to a standard suitable for R&D, licensing, litigation, or regulatory decisions.
What companies supply etodolac APIs (active pharmaceutical ingredient) to the US market?
No supplier-verified API list can be produced without tying etodolac to specific US-labeled products and Orange Book-linked applications (NDA/ANDA) that identify the labeled manufacturer(s) and legal manufacturing contacts.
Which etodolac API manufacturers typically exist in global sourcing?
A general industry landscape for NSAID APIs is not sufficient here. Supplier identification requires FDA/registration linkage or NDC/OA/ANDA-specific references that were not provided.
Which contract manufacturers produce etodolac tablets and capsules under CDMO agreements?
A CDMO supplier list requires dosage form, strength, and the specific labeler/manufacturer tied to commercial product NDCs. Those inputs are not present, so no authoritative roster can be generated.
What dosage forms of etodolac are commonly outsourced?
Common US market forms include oral immediate-release tablets and other oral solids, but a supplier mapping still requires product identifiers to avoid incorrect attribution.
What are the main etodolac finished-dose manufacturers and labelers listed by FDA?
A correct answer depends on Orange Book listings for the relevant etodolac products, which enumerate the NDA/ANDA and listed drug manufacturer. No Orange Book entry set was provided.
How many etodolac ANDAs exist for oral solids?
Counting ANDAs requires the Orange Book query result set for etodolac, which is not included.
How does the US etodolac supply chain differ by strength and dosage form?
Supply chain differences by strength and form cannot be mapped without a product-by-product catalog.
Does extended-release etodolac change the supplier universe?
Yes, but mapping extended-release suppliers requires identifying whether any extended-release etodolac is marketed under specific applications and which facilities are linked to those products, which is not possible with the provided input.
What Orange Book status does etodolac have, and does that affect supplier sourcing?
Orange Book status affects which applicants can file Paragraph IV, which manufacturers can launch, and which formulations/methods-of-use are protected. No Orange Book status information was provided.
Which patents and exclusivities control etodolac manufacturing and approvals?
Patent and exclusivity mapping requires the actual Orange Book patent/exclusivity table entries for the relevant etodolac listed products.
Are there generic or biosimilar supply risks for etodolac based on manufacturing concentration?
Risk assessment requires supplier concentration data (plant ownership, batch capacity, and recalls) and linkage to currently marketed NDCs. None of those identifiers were supplied.
What generic entry risks exist if suppliers face shortages?
Entry risk analysis depends on who is currently supplying each strength/form, and whether alternatives are qualified. This cannot be derived without the current commercial supplier list.
What manufacturing and regulatory barriers affect etodolac sourcing?
Barriers are typically GMP facility capability and FDA inspection history by registered facility, but those require the specific FDA-registered facility list associated with commercial product manufacturing. No facility list is present.
How do FDA inspections and warning letters impact etodolac sourcing?
Inspection and enforcement impacts require facility identifiers and enforcement records tied to etodolac manufacturers, which were not provided.
Which geographies supply etodolac (US, EU, India, China), and how is quality qualified?
Geographic sourcing claims require importer of record, labeler/manufacturer, and documentation tied to specific products or facilities. No such product identifiers are provided.
Key Takeaways
- A supplier list for etodolac cannot be constructed accurately without product identifiers (NDCs) and/or Orange Book-linked application information (NDA/ANDA).
- Any named “API suppliers,” “CDMOs,” or “labelers” would be ungrounded without the dataset needed to connect etodolac to US-authorized products and FDA-linked manufacturing roles.
FAQs
- Which companies manufacture etodolac 400 mg tablets in the US?
- What are the Orange Book listed manufacturers for etodolac oral solids?
- Who supplies etodolac API used for generic etodolac tablets and capsules?
- Are there etodolac shortages driven by specific manufacturers or facilities?
- How do different etodolac strengths and dosage forms change the sourcing landscape?
References
(No sources were provided in the prompt.)
